Boston-based Life Biosciences, co-founded by David Sinclair, has closed an $80 million Series D financing to fund its first-in-human clinical program and extend operations into 2027. The capital is allocated primarily to a Phase 1 trial of ER-100 in optic neuropathies and to further development of its Partial Epigenetic Reprogramming platform, which aims to modify cellular aging processes at the transcriptional level.
Prior to the current Series D raise, Life Bio raised a $82M Series C in 2022 and a $50M Series B round in 2019.
Life Biosciences was founded in 2017 and refers to its…
